Strategies to Accelerate the Path to Clinic for Next-Generation Antibodies
Summary: Some of the latest promising biopharmaceutical developments rely on antibody and antibody fragments that could be engineered for a variety of clinical applications. However, these next-generation antibodies, particularly antibody fragments, possess an increased level of complexities and technical challenges that may result in longer CMC development timelines and delay to clinical trials, as well as commercial launches.
In this webinar, experts discuss formulation development and purification strategies to increase throughput, reduce operating costs and potentially decrease development times for monoclonal antibody fragments.